Paclitaxel combined with carboplatin in the treatment of elderly and younger patients with advanced non-small cell Lung cancer

ZHU Ren,XU Jianfang,ZHOU Caicun
DOI: https://doi.org/10.3969/j.issn.1009-6663.2008.09.031
2008-01-01
Abstract:Objective To investigate the results of combined chemotherapy with carboplatin plus paclitaxel in treatment of chemotherapy-nave elderly and younger patients with advanced non-small cell lung cancer.Methods 100 NSCLC patients with stage IIIb and IV who had received chemotherapy in our hospital from Jan 2002 to Dec 2005 were retrospectively analyzed. Among them,50 cases with the age over 70 years old were in the elder group,while 50 cases with the age younger than 70 were in the younger group.They were treated with carboplatin plus paclitaxel.Results The response rates were 37.5% and 38.8%,respectively.In the patients older than 70 years old,and in the patients less than 70 years old were 38.8%,The median survival duration(MST)in the patients older than 70 years old was 11.8 ms,and the 1-,2-year survival rates (YST) were 31.3% and 6.3%.For the patients less than 70 years old,the respective figures were 11.3 ms,28.6%,4.1%.The main side effects were bone marrow depression.Conclusion The age factor can not influence the response rate of chemotherapy and the survival.or increase the bone marrow toxicity.
What problem does this paper attempt to address?